S100A16, a promising candidate as a prognostic marker for platinum-based adjuvant chemotherapy in resected lung adenocarcinoma

Abstract

PurposeAlthough cisplatin-based adjuvant chemotherapy improves the survival of patients with resected non-small-cell lung cancer, not all patients show a survival benefit, and some patients experience severe toxicity. Therefore, identifying biomarkers is important for selecting subgroups of patients who may show improved survival with platinum-based adjuvant chemotherapy. S100A16 is thought to play key roles during different steps of tumor progression. The aim of this study was to evaluate the use of S100A16 expression as a prognostic marker in patients with completely resected lung adenocarcinoma receiving platinum-based adjuvant chemotherapy.MethodsS100A16 expression was immunohistochemically studied in 65 consecutive lung adenocarcinoma patients who underwent complete resection and received platinum-based adjuvant chemotherapy. Kaplan–Meier survival analysis and Cox proportional hazards models were used to estimate the effect of S100A16 expression on disease-free survival (DFS) and overall survival (OS).ResultsS100A16 expression was detected in 26 of the 65 (40.0%) lung adenocarcinoma patients. Although S100A16 expression was not correlated with DFS (P=0.062), it was significantly correlated with OS (P=0.009). In addition, multivariable analysis revealed that S100A16 expression independently predicted a poorer survival (HR =4.79; 95% CI =1.87–12.23; P=0.001).ConclusionThe present study revealed that S100A16 is a promising candidate as a prognostic marker for platinum-based adjuvant chemotherapy in resected lung adenocarcinoma. A further large-scale study is needed to confirm the present results.

Aberrant S100A16 expression might be an independent prognostic indicator of unfavorable survival in non-small cell lung adenocarcinoma

“…Thus, S100A16 expression was set as a continuous variable in COX survival analysis. The following univariate and multivariate analysis confirmed the independent prognostic value of S 100A16 expression in terms of OS, which is consistent with the findings in two recent studies [ 7 , 8 ]. In addition, we also found that increased S100A16 expression was an independent prognostic indicator of unfavorable RFS (HR: 1.206, 95%CI: 1.045–1.393, p = 0.011), after adjustment of pathologic stage and residual tumors.…”

“…In colorectal cancer, membrane S100A16 expression might serve as an independent prognostic marker for overall survival (OS) [ 6 ]. Two recent studies (N = 170 and N = 65 respectively) observed that S100A16 is significantly upregulated in lung adenocarcinoma (LUAD) and might be an independent prognostic indicator of poor OS [ 7 , 8 ]. However, the small sample size limits their statistical power.…”

Prognostic values of S100 family members in ovarian cancer patients

“…S100A16 was a recent addition to the S100 family that isolated from astrocytoma [61]. The expression of S100A16 was upregulated in various tumors, such as bladder, lung, thyroid gland, pancreas, and so on [62, 63]. In lung adenocarcinoma, S100A16 expression was associated with vessel invasion and poor outcome and confirmed as an independent prognostic marker [62].…”

Identification of Prognostic Immune-Related Genes by Integrating mRNA Expression and Methylation in Lung Adenocarcinoma

“…Its abnormal expression could be found in lung cancer [21]. Specifically, high S100A16 expression was found to be significantly associated with a poor prognosis in lung cancer [22][23][24]. FGF2, also known as a basic fibroblast growth factor (FGF), is an important regulator of cell growth and differentiation under physiological and pathological conditions [25,26].…”